Sarepta Therapeutics Inc (NASDAQ:SRPT)
| 159.33 Delayed Data As of Aug 05 |  +2.16 / +1.38%Today’s Change | 72.05 Today|||52-Week Range 175.00 | +23.47% Year-to-Date |
Latest SRPT News | Press Releases
| Personalis: Buy This Disruptor In Precision Medicine And Machine Learning Jul 27 / Seeking Alpha - Paid Partner Content | Sarepta gene therapy Fast Track'd for Duchenne muscular dystrophy Jul 24 / Seeking Alpha - Paid Partner Content |
| Rising Risk? Here's What You Can Buy Jul 24 / Seeking Alpha - Paid Partner Content |
Today’s Trading
| Previous close | 156.73 |
| Today’s open | 156.91 |
| Day’s range | 154.07 - 159.50 |
| Volume | 571,072 |
| Average volume (3 months) | 860,525 |
| Market cap | $12.0B |
Data as of 3:59pm ET, 08/05/2020
Growth & Valuation
| Earnings growth (last year) | -77.81% |
| Earnings growth (this year) | +52.13% |
| Earnings growth (next 5 years) | +163.34% |
| Revenue growth (last year) | +26.51% |
| P/E ratio | NM |
| Price/Sales | 24.94 |
| Price/Book | 14.09 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| GLPGGalapagos NV | +1.90 | +1.00% |
| HZNPHorizon Therapeutics... | +14.59 | +23.61% |
| RDYDr.Reddy's Laborator... | -0.01 | -0.02% |
| CTLTCatalent Inc | +1.44 | +1.63% |
Data as of 4:33pm ET, 08/05/2020
Financials
| Last reporting date | August 6, 2020 |
| EPS forecast (this quarter) | -$1.72 |
| Annual revenue (last year) | $380.8M |
| Annual profit (last year) | -$715.1M |
| Net profit margin | -187.77% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Cambridge, Massachusetts |
Forecasts
